The study will evaluate the efficacy and safety of gevokizumab in treating active ulcers of pyoderma gangrenosum (PG).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
9
Unnamed facility
Oceanside, California, United States
Unnamed facility
Tampa, Florida, United States
Unnamed facility
Macon, Georgia, United States
The proportion of subjects at Day 126 with complete closure of the PG target ulcer confirmed 2 weeks later (at Day 140) and without the need for rescue treatment
Time frame: Day 126
The proportions of subjects at Day 126 with a reduction in the target ulcer area of ≥ 75% or ≥ 90% from baseline.
Time frame: Day 126
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
St Louis, Missouri, United States
Unnamed facility
Henderson, Nevada, United States
Unnamed facility
Rochester, New York, United States
Unnamed facility
The Bronx, New York, United States
Unnamed facility
Benowa, Queensland, Australia
Unnamed facility
Woolloongabba, Queensland, Australia
Unnamed facility
Parkville, Victoria, Australia
...and 6 more locations